Articles
17.01.2022
COVID-19 Two Year Review

As we enter 2022, we are approaching the two-year anniversary of the COVID-19 pandemic spreading acr...

Read more
Articles
10.01.2022
Conducting a HTA review

Reviewing previous HTA submissions can provide valuable insights that can help manufacturers prepare...

Read more
Articles
05.01.2022
Orphan Drugs and Diseases: 101

This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...

Read more
Articles
20.12.2021
The end of higher drug prices in the US

In the US, an Act recently passed through the House of Representatives which plans to expand afforda...

Read more
Articles
15.12.2021
Patent protection in the pharmaceutical industry

Patent cliff refers to a sharp decline in revenue or profitability when a firm’s patents expire, o...

Read more
Articles
03.12.2021
Reflecting on the Pricing & Market Access tren...

Our experts reflect on the pricing and market access trends that shaped the European Landscape in 20...

Read more
Publications
03.12.2021
Pricing and reimbursement policies for digital the

Digital therapeutics (DTx) is a category of digital health, which is defined as products that delive...

Read more
News
27.11.2021
PMA Insights: Week 43

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
News
24.11.2021
PMA Insights: Week 47 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
22.11.2021
NICE cost effective medicines

When making a decision about the approval of a new product NICE (National Institute for Health and C...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.